Raphael Pharmaceutical Inc.
RAPH · OTC
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $141 | $72 | $211 | $162 |
| G&A Expenses | $174 | $353 | $183 | $157 |
| SG&A Expenses | $174 | $353 | $183 | $157 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $315 | $425 | $394 | $319 |
| Operating Income | -$315 | -$425 | -$394 | -$319 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$7 | -$4 | -$1 | -$7 |
| Pre-Tax Income | -$322 | -$429 | -$395 | -$326 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$322 | -$429 | -$395 | -$326 |
| % Margin | – | – | – | – |
| EPS | -0.016 | -0.022 | -0.021 | -0.017 |
| % Growth | 25.1% | -6.3% | -18.4% | – |
| EPS Diluted | -0.016 | -0.022 | -0.021 | -0.017 |
| Weighted Avg Shares Out | 19,626 | 19,626 | 19,150 | 18,701 |
| Weighted Avg Shares Out Dil | 19,626 | 19,626 | 19,150 | 18,701 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $7 | $0 |
| Interest Expense | $7 | $4 | $0 | $7 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$315 | -$425 | -$394 | -$319 |
| % Margin | – | – | – | – |